Vaccines
Positive data from a Phase II/III trial of Bharat Biotech vaccine, Covaxin. Read more about the research and know about the efficiency of the vaccine.
Not surprisingly, there’s still plenty of interesting research coming out about COVID-19, but the end of 2021 also provided exciting science in other areas. Here’s a look.
Full results from the Phase III trial of Novavax’s proposed COVID-19 vaccine demonstrated the drug’s efficacy in preventing mild, moderate, and severe illness.
Another flu season, another less than effective flu vaccine. The shape-shifting virus has mutated already and this year’s flu vaccine is a poor match to fight it.
The avalanche of news released every day about all three - or various combinations thereof - can be overwhelming. So, BioSpace has put together a chart for easy comparative reference.
A recent study estimates that in the U.S. alone the vaccines saved 1.1 million lives and prevented 10.3 million hospitalizations. For that and more COVID-19 news, continue reading.
Although it’s not yet clear how dangerous the Omicron variant of COVID-19 actually is, it clearly is very infectious and rates are rising in the U.S. and around the world.
The lawsuit was filed by Public Health and Medical Professionals for Transparency, a nonprofit organization recently formed with a mission to obtain the data for the COVID-19 vaccines.
Despite the biggest vaccination drive in the U.S., the pandemic is still not over. The U.S. has reported more than 800,000 COVID-19 deaths, an increase of 500,000 since the vaccination started.
A study out of the University of Oxford found that two shots of the Pfizer-BioNTech vaccine or the AstraZeneca-Oxford vaccine were not as effective at against Omicron as they were against previous variants.
PRESS RELEASES